This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Neurology				
Neuropathic pain	Adenosine A ₁ receptor (ADORA ₁)	<p>An SAR study characterized a series of N⁶-cyclopentyl-adenosine and N⁶-(endo-norborn-2-yl) adenosine derivatives as ADORA₁ agonists that could help treat neuropathic pain. Several compounds had higher affinity and selectivity for ADORA₁ over other adenosine receptor subtypes when compared with their parent compounds. In a murine model of pain, one compound decreased nociceptive behavior compared with that seen in controls. Next steps include evaluating the compounds in other animal models of neuropathic pain.</p> <p>T-62, an adenosine A₁ allosteric enhancer from King Pharmaceuticals Inc., is in Phase II testing to treat neuropathic pain.</p> <p>SciBX 2(14); doi:10.1038/scibx.2009.592 Published online April 9, 2009</p>	Unpatented; unlicensed	<p>Franchetti, P. <i>et al. J. Med. Chem.</i>; published online March 24, 2009; doi:10.1021/jm801456g</p> <p>Contact: Mario Grifantini, University of Camerino, Camerino, Italy e-mail: mario.grifantini@unicam.it</p>